Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
Wu, Yi-Long, Prof, Zhou, Caicun, Prof, Hu, Cheng-Ping, Prof, Feng, Jifeng, Prof, Lu, Shun, Prof, Huang, Yunchao, Prof, Li, Wei, Prof, Hou, Mei, Prof, Shi, Jian Hua, Prof, Lee, Kye Young, Prof, Xu, Chong-Rui, MD, Massey, Dan, MSc, Kim, Miyoung, MD, Shi, Yang, MD, Geater, Sarayut L, MD
Published in The lancet oncology (01.02.2014)
Published in The lancet oncology (01.02.2014)
Get full text
Journal Article